Literature DB >> 11854698

Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer.

Pascal Gervaz1, Jean-Philippe Cerottini, Hanifa Bouzourene, Dieter Hahnloser, Christy L Doan, Jean Benhattar, Pascal Chaubert, Michelle Secic, Michel Gillet, John M Carethers.   

Abstract

BACKGROUND: At least 2 apparently independent mechanisms, microsatellite instability (MSI) and chromosomal instability, are implicated in colorectal tumorigenesis. Their respective roles in predicting clinical outcomes of patients with T3N0 colorectal cancer remain unknown.
METHODS: Eighty-eight patients with a sporadic T3N0 colon or rectal adenocarcinoma were followed up for a median of 67 months. For chromosomal instability analysis, Ki-ras mutations were determined by single-strand polymerase chain reaction, and p53 protein staining was studied by immunohistochemistry. For MSI analysis, DNA was amplified by polymerase chain reaction at 7 microsatellite targets (BAT25, BAT26, D17S250, D2S123, D5S346, transforming growth factor receptor II, and BAX).
RESULTS: Overall 5-year survival rate was 72%. p53 protein nuclear staining was detected in 39 patients (44%), and MSI was detected in 21 patients (24%). MSI correlated with proximal location (P <.001) and mucinous content (P <.001). In a multivariate analysis, p53 protein expression carried a significant risk of death (relative risk = 4.0, 95% CI = 1.6 to 10.1, P =.004). By comparison, MSI was not a statistically significant prognostic factor for survival in this group (relative risk = 2.2, 95% CI = 0.6 to 7.3, P =.21).
CONCLUSIONS: p53 protein overexpression provides better prognostic discrimination than MSI in predicting survival of patients with T3N0 colorectal cancer. Although MSI is associated with specific clinicopathologic parameters, it did not predict overall survival in this group. Assessment of p53 protein expression by immunocytochemistry provides a simple means to identify a subset of T3N0 patients with a 4-times increased risk for death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854698     DOI: 10.1067/msy.2002.119816

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  15 in total

1.  Better survival of right-sided than left-sided stage II colon cancer: a propensity scores matching analysis based on SEER database.

Authors:  Shuanhu Wang; Xinxin Xu; Jiajia Guan; Rui Huo; Mulin Liu; Congqiao Jiang; Wenbin Wang
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

2.  Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer.

Authors:  Mikel Garcia-Marcos; Barbara H Jung; Jason Ear; Betty Cabrera; John M Carethers; Pradipta Ghosh
Journal:  FASEB J       Date:  2010-10-25       Impact factor: 5.191

Review 3.  Different treatment strategies and molecular features between right-sided and left-sided colon cancers.

Authors:  Hong Shen; Jiao Yang; Qing Huang; Meng-Jie Jiang; Yi-Nuo Tan; Jian-Fei Fu; Li-Zhen Zhu; Xue-Feng Fang; Ying Yuan
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

4.  Study of the Annexin A1 and Its Associations with Carcinoembryonic Antigen and Mismatch Repair Proteins in Colorectal Cancer.

Authors:  Lenuce Ribeiro Aziz Ydy; Gilmar Ferreira do Espírito Santo; Ivana de Menezes; Michelle Santos Martins; Eliane Ignotti; Amílcar Sabino Damazo
Journal:  J Gastrointest Cancer       Date:  2016-03

5.  Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers.

Authors:  Barbara Jung; E Julieta Smith; Ryan T Doctolero; Pascal Gervaz; Julio C Alonso; Katsumi Miyai; Temitope Keku; Robert S Sandler; John M Carethers
Journal:  Int J Cancer       Date:  2006-05-15       Impact factor: 7.396

6.  Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon.

Authors:  Joel Pekow; Katherine Meckel; Urszula Dougherty; Fatma Butun; Reba Mustafi; John Lim; Charis Crofton; Xindi Chen; Loren Joseph; Marc Bissonnette
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-04       Impact factor: 4.052

7.  Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin.

Authors:  Manuela Pinheiro; Terje Ahlquist; Stine A Danielsen; Guro E Lind; Isabel Veiga; Carla Pinto; Vera Costa; Luís Afonso; Olga Sousa; Maria Fragoso; Lúcio Santos; Rui Henrique; Paula Lopes; Carlos Lopes; Ragnhild A Lothe; Manuel R Teixeira
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

8.  The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.

Authors:  Seung Tae Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Jin Yong Kim; Young Ho Kim; Dong Kyung Chang; Poong-Lyul Rhee; Dae Shick Kim; Haeran Yun; Yong Beom Cho; Hee Cheol Kim; Seong Hyeon Yun; Ho-Kyung Chun; Woo Yong Lee; Young Suk Park
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

9.  Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients.

Authors:  Masayoshi Miyoshi; Hideki Ueno; Yojiro Hashiguchi; Hidetaka Mochizuki; Ian C Talbot
Journal:  Ann Surg       Date:  2006-04       Impact factor: 12.969

10.  Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer.

Authors:  Ying Lin; Phillip J Buckhaults; Jeffrey R Lee; Hairong Xiong; Christopher Farrell; Robert H Podolsky; Robert R Schade; William S Dynan
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.